Kite Pharma (KITE) Offers Updated 12-Month Follow-Up Data from ZUMA-1 Phase 1 at ESMO
Tweet Send to a Friend
Kite Pharma, Inc. (Nasdaq: KITE) today announced updated results from the Phase 1 portion of Kite's ZUMA-1 clinical trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
